Intestinal Dysbiosis Disguised as a Rectal Fistula Treated With Autologous Fecal Microbiota Transplantation

2019 ◽

Vol 2019 ◽

pp. 1-4 ◽

Cited By ~ 1

Author(s):

Igor Alexander Harsch ◽

Peter Christopher Konturek

Keyword(s):

Fecal Microbiota Transplantation ◽

Fecal Microbiota ◽

Time Interval ◽

Short Time Interval ◽

Chronic Radiation ◽

Intestinal Dysbiosis ◽

Radiation Colitis ◽

Digestive Disorders ◽

Novel Strategy ◽

Short Time

Fecal microbiota transplantation (FMT) is a novel strategy for the therapy of dysbiosis-associated disorders via modulation of the gut microbiota. Intestinal dysbiosis is associated not only with digestive disorders, but also with a variety of extra-digestive disorders. A worldwide increasing number of FMT can be expected in the future as well as an increase in adverse events. We describe the case of a patient with chronic radiation colitis that developed adhesion ileus 2 days after FMT. Since these problems never occured before and the short time interval favours a causality, we speculate about FMT-induced alterations in gut motility causing a “trapping” of the small intestine in an adhesion and other mechanisms beyond “pure” coincidence.

Download Full-text

Fecal microbiota transplantation and bacterial consortium transplantation have comparable effects on the re-establishment of mucosal barrier function in mice with intestinal dysbiosis

Frontiers in Microbiology ◽

10.3389/fmicb.2015.00692 ◽

2015 ◽

Vol 6 ◽

Cited By ~ 26

Author(s):

Ming Li ◽

Pin Liang ◽

Zhenzhen Li ◽

Ying Wang ◽

Guobin Zhang ◽

...

Keyword(s):

Barrier Function ◽

Fecal Microbiota Transplantation ◽

Bacterial Consortium ◽

Fecal Microbiota ◽

Mucosal Barrier ◽

Intestinal Dysbiosis ◽

Mucosal Barrier Function

Download Full-text

Transplanting a Microbial Organ: the Good, the Bad, and the Unknown

mBio ◽

10.1128/mbio.00572-16 ◽

2016 ◽

Vol 7 (3) ◽

Cited By ~ 9

Author(s):

Dionysios A. Antonopoulos ◽

Eugene B. Chang

Keyword(s):

Inflammatory Bowel Disease ◽

Complex Disease ◽

Fecal Microbiota Transplantation ◽

Genetic Material ◽

Fecal Microbiota ◽

Unintended Consequences ◽

State Of Health ◽

Disease States ◽

Intestinal Dysbiosis ◽

Inflammatory Bowel

ABSTRACT Fecal microbiota transplantation (FMT) has received increased attention as a therapy for correcting intestinal dysbiosis and restoring a state of health in patients suffering from either recalcitrant infection by Clostridium difficile or more complex disease states, such as inflammatory bowel disease (IBD). The “gut microbial organ” from the donor that is used in these transplants may serve to transfer genetic material between donor and recipient via virus-like particles, specifically bacteriophages, that infect the bacterial component of the microbiota. The recently published study by Chehoud et al. provides evidence for not only the transfer of bacteriophages during FMT but also the transfer of multiple populations of bacteriophages to recipients from the donor microbiota used (C. Chehoud et al., mBio 7:e00322-16, 2016, http://dx.doi.org/10.1128/mBio.00322-16 ). While the clinical significance of these findings remains unclear, nothing short of a diligent and persistent effort is needed to define the intended and unintended consequences of FMT.

Download Full-text

OC.10.3: Fecal Microbiota Transplantation Via Enema for Recurrent Clostridium Difficile Infection Modulates the Inflammatory Host Response and Restores Intestinal Dysbiosis

Digestive and Liver Disease ◽

10.1016/s1590-8658(17)30354-7 ◽

2017 ◽

Vol 49 ◽

pp. e103 ◽

Cited By ~ 1

Author(s):

C. Cicerone ◽

G. Bruno ◽

L. Lamonaca ◽

A. D’Abramo ◽

A. Oliva ◽

...

Keyword(s):

Clostridium Difficile ◽

Clostridium Difficile Infection ◽

Host Response ◽

Fecal Microbiota Transplantation ◽

Fecal Microbiota ◽

Recurrent Clostridium Difficile Infection ◽

Intestinal Dysbiosis

Download Full-text

Fecal microbiota transplantation via enema for recurrent Clostridium difficile infection modulates the inflammatory host response and restore intestinal dysbiosis

10.26226/morressier.57c53841d462b80296c9b851 ◽

2016 ◽

Author(s):

Enrico Stefano Corazziari

Keyword(s):

Clostridium Difficile ◽

Clostridium Difficile Infection ◽

Host Response ◽

Fecal Microbiota Transplantation ◽

Fecal Microbiota ◽

Recurrent Clostridium Difficile Infection ◽

Intestinal Dysbiosis

Download Full-text

Fecal microbiota transplantation in the treatment of Clostridium difficile infection: state of the art and literature review

Revista do Colégio Brasileiro de Cirurgiões ◽

10.1590/0100-6991e-20181609 ◽

2018 ◽

Vol 45 (2) ◽

Cited By ~ 2

Author(s):

BRUNO AMANTINI MESSIAS ◽

BÁRBARA FREITAS FRANCHI ◽

PEDRO HENRIQUE PONTES ◽

DANIEL ÁTILA DE ANDRADE MEDEIROS BARBOSA ◽

CÉSAR AUGUSTO SANITA VIANA

Keyword(s):

Clostridium Difficile ◽

Intestinal Microbiota ◽

Clostridium Difficile Infection ◽

Fecal Microbiota Transplantation ◽

Physiological Mechanism ◽

Antibiotic Use ◽

Initial Therapy ◽

Fecal Microbiota ◽

Intestinal Dysbiosis ◽

The Cost

ABSTRACT Clostridium difficile infection is a common complication following intestinal dysbiosis caused by abusive antibiotic use. It presents medical importance due to the high rates of recurrence and morbidity. Fecal microbiota transplantation is an effective alternative for the treatment of recurrent and refractory C. difficile infection and consists of introducing the intestinal microbiota from a healthy donor into a patient with this infection. The exact physiological mechanism by which fecal microbiota transplantation alters the intestinal microbiota is not well established, but it is clear that it restores the diversity and structure of the microbiota by promoting increased resistance to colonization by C. difficile. Several routes of transplant administration are being studied and used according to the advantages presented. All forms of application had a high cure rate, and the colonoscopic route was the most used. No relevant complications and adverse events have been documented, and the cost-effectiveness over conventional treatment has proven advantageous. Despite its efficacy, it is not commonly used as initial therapy, and more studies are needed to establish this therapy as the first option in case of refractory and recurrent Clostridium difficileinfection.

Download Full-text